Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

675
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
675
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

328
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
328
Autoimmune Disorders01:29

Autoimmune Disorders

2.0K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

621
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
621
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

875
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
875
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

588
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
588

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modest, at best: The effect of getting rid of copays for antiplatelet drugs.

Managed care (Langhorne, Pa.)·2019
Same author

Emergency Care Examined.

Managed care (Langhorne, Pa.)·2019
Same author

A Conversation with Gary Lyman, MD: Biosimilars and the Search for the Cure To Cancer Treatment's Financial Toxicity.

Managed care (Langhorne, Pa.)·2019
Same author

A Wide Angle Lens on Adverse Events.

Managed care (Langhorne, Pa.)·2019
Same author

A Conversation With Mai Pham, MD. Payment Innovation at Anthem: Downside Risk Will Be Rewarded.

Managed care (Langhorne, Pa.)·2018
Same author

Q&A: A Conversation with Patrick J. Kennedy. Parity Advocate Sees More Talk Than Action.

Managed care (Langhorne, Pa.)·2018
Same journal

Thanks to CMS Rule Change, MA Takes SDOH to a Whole New Level.

Managed care (Langhorne, Pa.)·2019
Same journal

Hail, Not Frail! MA's Wellness Reach Expands.

Managed care (Langhorne, Pa.)·2019
Same journal

To Be Continued:The Search for a Cure for HIV.

Managed care (Langhorne, Pa.)·2019
Same journal

Once-a-day HIV Treatment: Pricey But Perhaps Worth It.

Managed care (Langhorne, Pa.)·2019
Same journal

In Trump, HIV/AIDS Groups Find an Ally Who's Tough To Love.

Managed care (Langhorne, Pa.)·2019
Same journal

Air Ambulance Turbulence: Consolidation, Cost Shifting, and Surprise Billing.

Managed care (Langhorne, Pa.)·2019
See all related articles

Related Experiment Video

Updated: Mar 8, 2026

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

10.0K

For Autoimmune Ills, Biologics Bring Promise-And Problems.

Katherine T Adams, Peter Wehrwein

    Managed Care (Langhorne, Pa.)
    |January 26, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Recombinant DNA technologies offer revolutionary treatments for autoimmune diseases like rheumatoid arthritis. However, these advanced therapies present significant cost challenges and potential side effects.

    More Related Videos

    Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
    06:26

    Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

    Published on: January 24, 2025

    2.0K
    Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
    10:10

    Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

    Published on: November 8, 2016

    9.3K

    Related Experiment Videos

    Last Updated: Mar 8, 2026

    Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
    12:36

    Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

    Published on: June 26, 2018

    10.0K
    Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
    06:26

    Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

    Published on: January 24, 2025

    2.0K
    Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
    10:10

    Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

    Published on: November 8, 2016

    9.3K

    Area of Science:

    • Biotechnology
    • Immunology
    • Pharmacology

    Background:

    • Recombinant DNA technology has significantly advanced medical treatments.
    • Autoimmune diseases, including rheumatoid arthritis, affect a large patient population.
    • Existing treatments may have limitations in efficacy or side effect profiles.

    Purpose of the Study:

    • To highlight the impact of recombinant DNA technologies on autoimmune disease treatment.
    • To discuss the benefits and drawbacks of these novel therapeutic approaches.

    Main Methods:

    • Review of current literature on recombinant DNA-based therapies.
    • Analysis of treatment outcomes for rheumatoid arthritis and other autoimmune conditions.
    • Evaluation of cost-effectiveness and side effect profiles of these medications.

    Main Results:

    • Recombinant DNA medications have transformed the management of rheumatoid arthritis and numerous other autoimmune diseases.
    • These therapies offer improved clinical outcomes for many patients.
    • Significant challenges include high medication costs and complex side effect management.

    Conclusions:

    • Recombinant DNA technologies represent a major breakthrough in treating autoimmune disorders.
    • Careful consideration of economic factors and patient safety is crucial for optimal implementation.
    • Further research may focus on mitigating costs and adverse effects for broader accessibility.